Lung Cancer diagnostic solutions
|
|
|
- このか そめや
- 6 years ago
- Views:
Transcription
1 Lung Cancer diagnostic solutions
2 1 Lung Cancer diagnostic solutions 1 ALK D5F c-met SP SP CD56 MRQ CEA TF3H CEA CEA LK2H Cytokeratin 5 SP /6 D5/16B Cytokeratin 5/14 EP1601Y/LL / Cytokeratin 14 SP SP SP Cytokeratin CAM EGFR 3C EGFR 5B EGFR E746-A750 del SP EGFR L858R SP EMA E Epithelial Related Antigen, ERA MOC Epithelial Specific Antigen, Ep-CAM Ber-EP IGF-1R G Mesothelial Cell HBME Napsin A MRQ NSE MRQ p40 BC P63 4A Cytokeratin Pan-keratin AE1, AE3, PCK Synaptophysin MRQ TAG-72 B TTF-1 SP WT-1 6F-H I-VIEW CEA TF3H AMX ultraview CEA TF3H AMX I-VIEW Cytokeratin Pan-keratin AE1,AE3,PCK AMX ultraview Cytokeratin Pan-keratin AE1,AE3,PCK AMX
3 Lung Cancer diagnostic solutions % NSCLC80 85% 1 SCLC15 20% 1 3 EGFR ALK 4 15% 2 NSCLC SCLC 15% 1 NSCLC 85% % H&E 6 60% 1 40% 1 EGFR ALK KRAS PD-L1 ROS1
4 3 Lung Cancer diagnostic solutions NSCLC Squamous cell carcinoma stained with p40 BC28 using OptiView DAB IHC detection Squamous cell carcinoma stained with CK 5/6 D5/16B4 p40bc28 5/6D5/16B4 p40 ( BC28) P63 7,8 p40 BC28 Cytokeratin 5/6 TTF-1 Napsin A 9 5/6D5/16B Squamous cell carcinoma stained with P63 4A4 Squamous cell carcinoma stained with CK 5/14 EP1601Y/LL002 P634A4 P634A4 p63 Cytokeratin 5/14 EP1601Y/LL
5 Lung Cancer diagnostic solutions 4 NSCLC Adenocarcinoma stained with TTF-1 SP141 Adenocarcinoma stained with Napsin-A MRQ-60 TTF-1SP141 Napsin AMRQ-60 TTF-1 TTF-1SP141 Napsin A Napsin A Napsin A TTF-1SP141 SP141 8G7G3/1 YeNapsin A Napsin A TTF Dr. Shalini Singh Ventana Medical Systems
6 5 Lung Cancer diagnostic solutions NSCLC ALK c-met Adenocarcinoma stained with ALK D5F3 Adenocarcinoma stained with c-met SP44 ALKD5F3 c-metsp44 ALKD5F3 ALK c-metsp44 c-met ALKD5F3 NSCLC ALK ALK296 D5F3 ALK FISH 100% 11 HGF MET ADC70% SCC 40% c-met c-met 12 IHC SP % IHCALK FFPEMET FISH 11
7 Lung Cancer diagnostic solutions 6 NSCLC EGFR Adenocarcinoma stained with EGFR 3C6 Adenocarcinoma stained with EGFR 5B7 Adenocarcinoma stained with EGFR E746-A750 del SP111 Adenocarcinoma stained with EGFR L858R SP125 EGFR EGFR EGFR E746-A750 del EGFR L858R 3C6 5B7 SP111 SP125 EGFR3C6 EGFR5B7 EGFR E746-A750 del EGFR L858R 170 kd EGFR EGFR SP111 SP125 IgG1 145 kd III EGFR EGFR EGFR E746-A750 del EGFR L858R EML4-ALK EGFR 11,12 ALK EGFR EGFR EGFR 17
8 7 Lung Cancer diagnostic solutions NSCLC p40 BC28 P63 4A4 5/6 D5/16B4 Cytokeratin 5/14 EP1601Y/LL002
9 Lung Cancer diagnostic solutions 8 TTF-1 SP141 Napsin A MRQ-60 ALK ALK D5F3
10 9 Lung Cancer diagnostic solutions SCLC CD56MRQ-42 SP65 CD56MRQ-42 NK NK T LK2H10 7SP52 C 7SP NSEMRQ-55 20SP33 NSE 20SP33 18 SynaptophysinMRQ-40 WT16F-H2 SynaptophysinMRQ-40 WT111p13 WT16F-H2
11 Lung Cancer diagnostic solutions 10 1., ganjoho.jp 2. National Cancer Institute. General Information About Small Cell Lung Cancer. 2013; healthprofessional. 3. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer. Version Pao W, Hutchinson KE. Chipping Away at the Lung Cancer Genome. Nat Med 18 3 : Tacha D, Yu C, Bremer R, Qi W, Haas T. A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20: Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14: Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22: Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115: Leong AS, Phillips GE, Pieterse AS, Milios J.Criteria for the diagnosis of primary endocrinecarcinoma of the skin Merkel cell carcinoma. A histological, immunohistochemical andultrastructural study of 13 cases. Pathology. 1986;18: Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol. 2009;4: Bishop, Justin A, Julie Teruya-Feldstein, William H Westra, Giuseppe Pelosi, William D Travis and Natasha Rekhtman. p40np63 is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology Chen, Xiangbai, Yunhau Bao, Rebecca Wong, Katerina Politi, Lizhuo Jiao, Scott Gettinger, Robert Homer, David Chieng, Guoping Cai. [351] The Role of p40 Immunostain in the Cytological Differential Diagnosis of Squamous Cell Carcinoma and Adenocarcinoma of the Lung. USCAP Abstract Wei Zhao, Hui Wang, Yan Peng, Bo Tian, Lei Peng, Da-Chuan Zhang. Np63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens. Int J Clin Exp Pathol 2014;7 7 : Ye et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastaticcarcinoma in the lung. Appl Immunohistochem Mol Morphol Jul;19 4 : doi: / PAI.0b013e318205b Minca et al. ALK Status Testing in Non Small Cell Lung Carcinoma Correlation Between Ultrasensitive IHC and FISH. J Mol Diagn. 2013; jmoldx Tsuta K, Kozu Y, Mimae T, et al. c-met/ phospho-met protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol. 2012;7: Koeppen H, Januario T, Filvaroff E. Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer. Mod. Pathol. 2012; 25; 480A. 14. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:
12 VENTANA 1059.TD.TMS.1700.GEN01-003A
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
Fig. 1. Chest X-ray film on admission showed a mass in the left middle lung field and multiple nodular densities in the bilateral lung fields. Fig. 3.
A Case of Slow-growing Mucous-producing Adenocarcioma of the Lung Key words: Mucous-producing lung adenocarcinoma, Slow-growing, Bronchial gland cell type adenocarcinoma, Adenoid cystic carcinoma Table
DakoLink
PATHOLOGY DakoLink IHC FROM CERTAINTY COMES TRUST 2 / DakoLink IHC Solution Where quality meets productivity 40 IHC DakoLink IHC DakoLink IHC DakoLink IHC Introduction DakoLink IHC Solution / 3 A IHC IHC
untitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
E3200 BV FOLFOX4 FOLFOX4 PFS % 0.42, 0.65 p< log-rank % FOLFOX4 8.6% FOLFOX % FOLFOX4 259/ % FOL
E3200 BV FOLFOX4 FOLFOX4 PFS 4.5 7.5 0.518 95% 0.42, 0.65 p
スライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
2 W.T T.S. 70 2 1 238 WBC7400/µl, RBC 386 10 4 /µl, Hb 11.6 g/dl, Ht 36.2%, PLT 25 10 4 /µl AST 19 IU/l, ALT 11 IU/l, LDH 182 IU/l, BUN 15 mg/dl, Cr 0.54 mg/dl, CRP6.83 mg/dl, RF 353.9IU/ml, CCP 28.0IU/ml
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
Expression of PCNA and c-erbb- 2 in mucoepidermoid carcinoma of salivary glands: An immunohistochemical study Shigeru YAMABE E Akio MIZUNO E Shuichi FUJITA* Hiroshi TAKAHASHI* E Haruo OKABE* Abstract:
_08長沼.indd
35, 37-41, 2015 1 4 3 4.5 3 cm 1 2, 3 4 3 40 5 CT FNABC 1 3 1. 38 し 核異型の少ない濾胞構造を多数認めた 図 5, 考 6 形態的には腺腫様甲状腺腫様であったが 濾 察 胞癌の転移と診断された 転移が確認されたリン 甲状腺の単発性結節には濾胞腺腫 硝子化索状 パ節は I 番 II III 番 右 IV 番 右 Va で 郭清 腺腫等の良性腫瘍
分子病理診断: 進化し続けるバイオマーカー
第 27 回がん臨床研究フォーラム 肺がん診療最前線 : 過去 現在 そして未来は? 平成 29 年 6 月 9 日 ( 金 ) 国立がん研究センター内国際研究交流会館 分子病理診断 : 進化し続けるバイオマーカー 谷田部恭 (YATABE, Yasushi) 愛知県がんセンター遺伝子病理診断部 肺癌治療の変遷 Nat Rev Clin Oncol. 2015 Sep;12(9):511-26 肺癌診断の一例
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
PowerPoint プレゼンテーション
2017/6/9 第 27 回がん臨床研究フォーラム 大阪国際がんセンター 呼吸器内科西野和美 2017/6/9 第 27 回がん臨床研究フォーラム CO I 開示 大阪国際がんセンター西野和美 講演料 中外製薬ベーリンガーインゲルハイムアストラゼネカイーライリリー 肺癌薬物治療の変遷 Target Therapy Immunotherapy 1 次治療 ゲフィチニブ (EGFR-TKI) ペムブロリズマブ
1) Garner J. S.: The Hospital Infection Control Practices Advisory Committee, CDC, Guidelines for Isolation Precautions in Hospitals, 1996. http://wonder.cdc.gov/wonder/prevguid/ p0000419/p0000419.asp.
化学療法剤の適切な使い方について
1 2 3 4 5 6 7 Che E, in Cancer: Principles & Practice of Oncology (7th ed) in Devita, 2005 Marangolo M, Oncol Rep, 2006 hryniuk WM, Important Adv Oncol, 1988 8 Cancer: Principles & Practice of Oncology
膵癌超音波診(案)
1 2 3 4 5 6 7 8 9 10 2009 7 6 2 a. invasive ductal carcinoma * 1 b. endocrine neoplasm c. Solid pseudopapillary neoplasm d. tumor producing pancreatitis * 2 * 1 invasive ductal carcinomas papillary adenocarcinoma
1 1 tf-idf tf-idf i
14 A Method of Article Retrieval Utilizing Characteristics in Newspaper Articles 1055104 2003 1 31 1 1 tf-idf tf-idf i Abstract A Method of Article Retrieval Utilizing Characteristics in Newspaper Articles
26 1 : Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hira
26 1 : 35 45 2017 1 2 2 2 2 2 2 2 2 1 1 2 Self - reported Practices of Cancer Pain Management among Nurses in Tohoku University Hospital Hideyuki Hirayama 1, Yoko Nakajo 2, Akemi Saito 2, Rie Hatakeyama
- 2 -
- 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - A) B) C) D) E) F) - 10 - G) H) I) J) P - 11 - 001 1,416,0003/4 1,062,000 002 100,000 50,00023 1,150,000 2,100,000 200,000+ 100,0000.9 1,600,000 JA
名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
untitled
No.16 TBS TBS TBS 1 2 2 Low High 2 3 TBS ASC-USASC-H TBS TBS TBS TBS ASCASC-US,ASC-H TBS ASC ASC LSIL ASC-US HSIL ASC-H ASC 1 ASC HPV HPV TBS HPV HPV ASC-US ASC-US ASC-H ASC-US ASC-US ASC-H ASC-H
1 ) Birnberg et al; Am. J. Obst. Gyn., 54 :88E 1947. 2) Bromberg, Y.M. & Bercovici, B. : Acta Endocrin., 7; 71, 1956. 23 : 33, 1956; Fertil. and Steril. 3) Fluhmann, C. F. : The management of menstrual
HPV HPV HPV HPV 7 HPV 8 9 HPV 3 HPV HPV HPV , Becker Ajzen H
3 26 3 Journal of Junshin Gakuen University, HPV Faculty of Health Sciences Vol.3, March 2014 99 HPV Knowledge of and attitudes towards human papillomavirus vaccinations among mothers who have daughters
表1.eps
Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol
Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth
Studies of Foot Form for Footwear Design (Part 9) : Characteristics of the Foot Form of Young and Elder Women Based on their Sizes of Ball Joint Girth and Foot Breadth Akiko Yamamoto Fukuoka Women's University,
ÿþ
Abstract The aim of this paper is to describe 1. how media, especially mobile phones, have been utilized in childrearing practices, and 2. how the process of adoption influences the placement of techno-social
小児感染免疫第25巻第2号
2013 Vol. 25No. 2175 44 1972 28 1 Kikuchi s diseasekikuchifujmoto diseasehistiocytic necrotizing lymphadenitis Histiocytic necrotizing lymphadenitis, Kikuchi s disease, KikuchiFujimoto disease, subacute
_念3）医療2009_夏.indd
Evaluation of the Social Benefits of the Regional Medical System Based on Land Price Information -A Hedonic Valuation of the Sense of Relief Provided by Health Care Facilities- Takuma Sugahara Ph.D. Abstract
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
雇用不安時代における女性の高学歴化と結婚タイミング－JGSSデータによる検証－
日 本 版 General Social Surveys 研 究 論 文 集 [6] JGSS で 見 た 日 本 人 の 意 識 と 行 動 JGSS Research Series No.3 JGSS Women s Higher Education and Marriage Timing in an era of employment uncertainty Yuko NOZAKI Graduate
1) van Meer, G., Op den Kamp, J. A.: J. Cell. Biochem., 19, 193-2040982) 2) Gaffet, P., Bettache, N., Bienvenue, A.: Biochemistry, 34, 6762-6769(1995) 3) Sims, P. J., Wiedmer, T.: Thromb. Haemost., 86,
Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad
Key words: Female with bladder irritability, Subjective symptoms, Pyuria, Bacteriuria Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution
IonTorrentPGM_appnote_0319.indd
Ion PGM Heterogeneity * 1 * 1 * 2 * 2 * 2 * 2 * 2 * 1 *1 * 2 DNA DNA DNA ArcturusXT LCM Laser Capture Microdissection LCM A Workflow for Cancer Profiling Applied Biosystems ViiA7 PCR qpcr QC Assay Ion
Unknown
Journal of Breast and Thyroid Sonology Journal of Breast and Thyroid Sonology Vol.2, No.3 July 2013 Report The 30 th Meeting of Japan Association of Breast and Thyroid Sonology... 1 Department of Organ
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
Ⅱ Hb 4.1g/dl S LST G S ESD 10 S S 4 4 S D mL tub1 muc SS ly0 v0 PM0 DM0 N0 0/27 S tub1 tub2 SS
92 183 188 2016 1 1,2) 1) 1) 1) 1) 1) 3) 1) 2016 2 1 2016 3 11 84 S 2011 10 S 30 40 2 tub1 muc SS ly0 v0 PM0 DM0 N0 0/27 S 30 30 2 tub1 tub2 SS ly0 v0 PM0 DM0 N0 0/19 stage tub1 M ly0 v0 HM0 VM0 stage
EVALUATION OF NOCTURNAL PENILE TUMESCENCE (NPT) IN THE DIFFERENTIAL DIAGNOSIS OF IMPOTENCE Masaharu Aoki, Yoshiaki Kumamoto, Kazutomi Mohri and Kazunori Ohno Department of Urology, Sapporo Medical College
Core Ethics Vol.
Core Ethics Vol. < > Core Ethics Vol. ( ) ( ) < > < > < > < > < > < > ( ) < > ( ) < > - ( ) < > < > < > < > < > < > < > < > ( ) Core Ethics Vol. ( ) ( ) ( ) < > ( ) < > ( ) < > ( ) < >
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
2003 Giemsa HE HE AE1+AE3 HBME1 HE HE Well differentiated adenocarcinoma of colon Giemsa HE HE 62 Group V HE 47 Group V Peritoneal dissemination of gastric cancer HE 51 Poorly differentiated Adenocarcinoma(por2)
日本呼吸器学会誌第3巻第1号
16 特集 変化する肺癌治療 Topics 2 病理診断最新情報 腺癌新分類の動向と, 新しい遺伝子変化を有する肺腺癌の形態像 谷田部 恭 要旨 : 肺癌治療における病理診断の役割は癌の診断に始まり, 個別化医療の患者選択に及ぶ. そのなかにおいて,2011 年に提言された肺腺癌の新分類は重要な役割を果たし, その検証が行われつつある. その結果では, 新設された AIS,MIA については,5 年生存率
indd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly notified cases of all fo
Kekkaku Vol. 79, No. 1: 17-24, 2004 17 (Received 21 Aug. 2003/Accepted 18 Nov. 2003) Fig. 1 Trends of TB incidence rates for all forms and smear-positive pulmonary TB in Kawasaki City and Japan. Incidence=newly
6 1Bulletin of Tokyo University and Graduate School of Social Welfarepp73-86 2015, 10 372-0831 2020-1 2015 5 29 2015 7 9 : : : 1 A B C D E 4 A B A B A B A ] AB C D E 4 8 73 17 2 22 750 1 2 26 2 16 17 32
untitled
260 250 200 150 10 100 50 0 1960 1965 1970 1975 1980 1985 1985 1995 2000 2005 25% 56% 66% 60% 90 80 70 60 50 40 30 20 10 0 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1999 1990 2003 2005 2010 500,000 70,000 100,000
顔面神経麻痺を来したMPO―ANCA 陽性の中耳炎２症例
11367 : MPOANCA MPO ANCA MPOANCA 134EU MPO ANCA 67EU MPOANCA ANCA : MPOANCAANCA antineutrophil cytoplasmic antibody ; ANCA Davies IgG ANCA PR3proteinase3ANCA MPOmyeloperoxidaseANCA Wegener PR3ANCA MPO
,,,km Independent StateIndependent LoLo ,m,mm H .. cm ( ) ( ) ( ) () ( ) ( ) ( ) ( ) ( ) ( ) () () () () () () () () () () () () () () () () () () () () () () [ ] [ ] [ ] [ ] [ ] [ ] [ ] [
_’£”R‡Ù‡©
29 31 38 2008 31 1) 2) 2) 3) 2) 1) 2008 302008 12 Activities of Daily Living ADL ADL 42 ADL ADL 1990 QOL Quality of Life QOL 1 QOL // 2 Activity of Daily Living ADL Performance Status PS ADL 3 1) 2) 3)
第18回抗悪性腫瘍薬開発フォーラム 次世代テクノロジーは抗がん剤開発に何をもたらすか？ ～分子生物学的臨床開発基盤構築に向けて～
第 18 回抗悪性腫瘍薬開発フォーラム次世代テクノロジーは抗がん剤開発に何をもたらすか? ~ 分子生物学的臨床開発基盤構築に向けて ~ イントロダクション 次世代テクノロジーによるがん研究と課題 国立がん研究センター EPOC 土原一哉 第一部 : 新技術を用いた臨床開発 本邦におけるクリニカルシーケンスの現状と課題吉野孝之 ( 国立がん研究センター東病院 ) NCI-MATCH~ 米国 NCI の取組み
「適正なHER2検査のために」
乳癌における HER2 病理組織標本作製および 病理診断のガイドライン ( 案 ) 1. はじめに p. 2 2. 標本の準備 p. 2 3. Immunohistochemistry (IHC) 法 p. 2 4. In situ hybridization (ISH) 法 (FISH 法 DISH 法 ) p. 4 5. 病理診断と HER2 分子標的治療適応のフローチャート p. 6 6. 参考文献
DISTRIBUTION OF NEUROPEPTIDES IN THE INFERIOR NASAL TURBINATE MUCOSA OF PATIENTS WITH ALLERGIC RHINITIS KAZUHIRO YAMAMOTO. M.D. Department of Otolaryngology, School of Medicine, Kitasato University, Sagamihara
Core Ethics Vol.
Core Ethics Vol. Core Ethics Vol. . % % % Core Ethics Vol. %, Core Ethics Vol. % % % -. %. Core Ethics Vol. a b : Core Ethics Vol. pp... pp.. pp... pp. pp.. pp...pp.... pp. pp. pp.. pp.. Vol.. pp... pp..
II A LexisNexis JP 80, /03/
1 20 I II III 1 2 3 4 IV I Makiko Noto / 1 1933 8 2 2004 16 3 1 1963 101 118 11 1965 291 332 2 4 1985 247 262 3 446 2 3 465 2 465 5 2004 16= 2005 2005 004 2012 summer / No.392 3 4 5 80 6 7 5 20 8 II A
The Bulletin of the Institute of Human Sciences, Toyo University, No. 7 The Semantic Role and Function of GA and WO as object markers in Japanese WANG Yaxin The purpose of this paper is to analyze the
LM358
LM358 2 DC LM358 5V DC 15V DC micro SMD (8 micro SMD) LM358 LM2904 LM258 LM158 20000801 19870224 33020 23900 11800 2002 3 ds007787 Converted to nat2000 DTD added avo -23 to the first page Edited for 2001